Ligand Pharmaceuticals Inc (LGND)
116.55
+4.99
(+4.47%)
USD |
NASDAQ |
Nov 21, 16:00
116.89
+0.34
(+0.29%)
After-Hours: 20:00
Ligand Pharmaceuticals Revenue (Quarterly): 51.81M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 51.81M |
| June 30, 2024 | 41.53M |
| March 31, 2024 | 30.98M |
| December 31, 2023 | 28.10M |
| September 30, 2023 | 32.87M |
| June 30, 2023 | 26.37M |
| March 31, 2023 | 43.98M |
| December 31, 2022 | 50.38M |
| September 30, 2022 | 59.22M |
| June 30, 2022 | 50.13M |
| March 31, 2022 | 36.52M |
| December 31, 2021 | 36.88M |
| September 30, 2021 | 64.84M |
| June 30, 2021 | 84.68M |
| March 31, 2021 | 55.15M |
| December 31, 2020 | 47.13M |
| September 30, 2020 | 41.85M |
| June 30, 2020 | 41.42M |
| March 31, 2020 | 33.16M |
| December 31, 2019 | 27.00M |
| September 30, 2019 | 24.81M |
| June 30, 2019 | 24.99M |
| March 31, 2019 | 43.48M |
| December 31, 2018 | 59.59M |
| September 30, 2018 | 45.66M |
| Date | Value |
|---|---|
| June 30, 2018 | 90.04M |
| March 31, 2018 | 56.16M |
| December 31, 2017 | 50.46M |
| September 30, 2017 | 33.38M |
| June 30, 2017 | 28.00M |
| March 31, 2017 | 29.27M |
| December 31, 2016 | 38.19M |
| September 30, 2016 | 21.62M |
| June 30, 2016 | 19.52M |
| March 31, 2016 | 29.65M |
| December 31, 2015 | 21.19M |
| September 30, 2015 | 17.70M |
| June 30, 2015 | 18.42M |
| March 31, 2015 | 14.60M |
| December 31, 2014 | 23.00M |
| September 30, 2014 | 14.97M |
| June 30, 2014 | 10.61M |
| March 31, 2014 | 15.96M |
| December 31, 2013 | 14.74M |
| September 30, 2013 | 13.00M |
| June 30, 2013 | 9.58M |
| March 31, 2013 | 11.65M |
| December 31, 2012 | 13.64M |
| September 30, 2012 | 6.375M |
| June 30, 2012 | 5.742M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
26.37M
Minimum
Jun 2023
84.68M
Maximum
Jun 2021
44.20M
Average
41.69M
Median
Revenue (Quarterly) Benchmarks
| Regeneron Pharmaceuticals Inc | 3.721B |
| Agios Pharmaceuticals Inc | 8.964M |
| ADMA Biologics Inc | 119.84M |
| Pieris Pharmaceuticals Inc | -- |
| AnaptysBio Inc | 30.02M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -7.172M |
| Total Expenses (Quarterly) | 40.86M |
| EPS Diluted (Quarterly) | -0.39 |
| Enterprise Value | 1.983B |
| Gross Profit Margin (Quarterly) | 95.27% |
| Profit Margin (Quarterly) | -13.84% |
| Earnings Yield | 2.15% |
| Operating Earnings Yield | 0.85% |
| Normalized Earnings Yield | -0.7195 |